ResMed announces record financial results for 2012

ResMed has experienced a record operational performance during the most recent fiscal quarter, contributing to benchmark annual results for the firm.

The company's revenue for the three months ending on June 30th 2012 came to $371.9 million (237.8 million pounds), up by nine percent year on year, while income rose by 31 percent to a record $76.8 million.

For the whole year, revenues rose by ten percent to $1.37 billion, with growth attributed to strong performances in both the flow generator and mask categories.

Dr Peter Farrell, chairman and chief executive officer of ResMed, said: "In the fourth quarter of fiscal 2012 we showed strong year-over-year growth on the top and bottom line."

He added that he believes products such as ResMed's which treat sleep-disordered breathing should become more prevalently used, with recent clinical studies showing that the condition can be seriously debilitating at best and life-threatening at worst.

In June, the company expanded its product range with the US launch of Narval CC, a state-of-the-art mandibular repositioning device.